drugset / Trial / NCT03901690
Betaglucin 0.2% Versus Imiquimod 5% in Treatment of Ano-genital Warts: Combined Results From Triple Blind Controlled Study
Phase 3
Unknown
102 enrolled
Centro de Investigaciones Medicas y Ensayos Clinicos Dr Italo Fabbri
Bioanalisis · collabCALOX Laboratories · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
In order to determine the Efficacy of Betaglucin 0.2% in gel vs Imiquimod 5% cream in the treatment of 102 individuals older than 18 years with anogenital warts trials in two arms 51 with Betaglucin 0.2% and 51 with Imiquimod 5%.
Timeline
- Start
- 2019-08-27
- Primary completion
- 2020-03-10
- Completion
- 2020-05-20
Publications
- Background Baker DA, Ferris DG, Martens MG, Fife KH, Tyring SK, Edwards L, Nelson A, Ault K, Trofatter KF, Liu T, Levy S, Wu J. Imiquimod 3.75% cream applied daily to treat anogenital warts: combined results from women in two randomized, placebo-controlled studies. Infect Dis Obstet Gynecol. 2011;2011:806105. doi: 10.1155/2011/806105. Epub 2011 Aug 24.
- Results Scardamaglia P, Carraro C, Mancino P, Stentella P. [Effectiveness of the treatment with beta-glucan in the HPV-CIN 1 lesions]. Minerva Ginecol. 2010 Oct;62(5):389-93. Italian.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Betaglucin | Unknown | 0.2 % | Topical |
| Subject | Betaglucin | Unknown | 5 g | Topical |
| Comparator | Imiquimod | Other / unclassified | 5 % | Topical |
| Comparator | Imiquimod | Other / unclassified | 1 g | Topical |